Cytosorbents Corporation CTSO
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -64.48%
- 1 year
- -70.97%
- Open
- 4.39
- Prev close
- 4.54
- Mkt cap
- 14.31M
- Vol
- 24.11K
- Avg vol
- 33.22K
- EPS
- -5.80
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 4.35
- High
- 4.70
- Forward P/E
- -5.99
- Beta
- 0.56
- Short ratio
- 9.57
- Inst. own
- 33.29%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.95762
- 200-d avg
- 0.981655
- 1y target
- 5.00
1M chart
Signals (9)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 29, 2026 | 3 days ago |
| SMA: Bullish | Oct 27, 2026 | 5 days ago |
| SMA: Bearish | Oct 26, 2026 | 6 days ago |
| SMA: Bearish | Oct 23, 2026 | 1 week ago |
| SMA: Bullish | Oct 22, 2026 | 1 week ago |
| SMA: Bullish | Oct 16, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 16, 2026 | 2 weeks ago |
| MACD: Sell Signal | Oct 14, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 12, 2026 | 2 weeks ago |
Key statistics
- Market cap
- 46.07M
- Enterprise value
- 71.15M
- Trailing P/E
- 0.00
- Forward P/E
- -5.99
- PEG ratio
- 0.00
- Price / sales
- 1.22
- Price / book
- 3.51
- EPS (TTM)
- -0.36
- Beta
- 0.56
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -49.47%
- Revenue (TTM)
- 37.74M
- Revenue growth
- 6.60%
- Free cash flow
- -11.95M
- Total cash
- 5.69M
- Total debt
- 26.81M
- Return on equity
- -118.50%
- Shares outstanding
- 54.95M
- Short % of float
- 2.58%
- 50-day average
- 0.95762
- 200-day average
- 0.981655
Analyst view
Consensus: buy
- Target (low)
- 1.00
- Target (mean)
- 5.00
- Target (high)
- 10.00
- Strong buy0
- Buy1
- Hold1
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.07.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.07 | -0.08 | -0.01 | -14.29% |
| Aug 13, 2024 | Jun 1, 2024 | -0.09 | -0.08 | +0.01 | +11.11% |
| May 9, 2024 | Mar 1, 2024 | -0.12 | -0.12 | 0.00 | 0.00% |
| Mar 14, 2024 | Dec 1, 2023 | -0.14 | -0.12 | +0.02 | +14.29% |
| Nov 9, 2023 | Sep 1, 2023 | -0.12 | -0.21 | -0.09 | -75.00% |
| Aug 1, 2023 | Jun 1, 2023 | -0.11 | -0.14 | -0.03 | -27.27% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 12, 2024 | D. Boral Capital | main | Buy | Buy |
| Nov 11, 2024 | HC Wainwright & Co. | reit | Neutral | Neutral |
| Nov 8, 2024 | EF Hutton | main | Buy | Buy |
| Nov 4, 2024 | EF Hutton | main | Buy | Buy |
| Oct 22, 2024 | EF Hutton | main | Buy | Buy |
| Oct 1, 2024 | EF Hutton | main | Buy | Buy |
About Cytosorbents Corporation
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- cytosorbents.com
News
- CytoSorbents to Report Third Quarter 2026 Financial Results and Recent Business Highlights
- 12 Health Care Stocks Moving In Friday's After-Market Session
- WBB Securities Initiates Coverage On CytoSorbents with Speculative Buy Rating, Announces Price Target of $9.5
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- 12 Health Care Stocks Moving In Monday's Intraday Session
- 12 Health Care Stocks Moving In Friday's Intraday Session
- Cytosorbents (NASDAQ:CTSO) versus Electromed (NYSE:ELMD) Head to Head Comparison
- Head to Head Survey: Zynex (NASDAQ:ZYXI) & Cytosorbents (NASDAQ:CTSO)
- CytoSorbents Announces New Data Presentations at Upcoming International Conferences in Cardiac Surgery and Critical Care
- CytoSorbents Regains Nasdaq Compliance
Your note
Sign in to keep a note on CTSO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BATOR MICHAEL G. | Director | Purchase | Dec 12, 2023 | 125,394 |
| BLOCH KATHLEEN P | Chief Financial Officer | Stock Award(Grant) | Apr 1, 2024 | 532,941 |
| CAPPONI VINCENT J | President | Stock Award(Grant) | Apr 1, 2024 | 665,134 |
| CHAN PHILLIP P | Chief Executive Officer | Stock Award(Grant) | Apr 1, 2024 | 1,164,700 |
| DELIARGYRIS EFTHYMIOS | Officer | Stock Award(Grant) | Apr 1, 2024 | 409,433 |
| JONES EDWARD RAYMOND M.D. | Director | Purchase | Dec 12, 2023 | 88,834 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Avenir Corp | 5.44% | 2,975,559 | 2.49M | Sep 29, 2024 |
| Skylands Capital, LLC | 5.04% | 2,755,427 | 2.31M | Sep 29, 2024 |
| Granahan Investment Management LLC | 3.83% | 2,094,882 | 1.76M | Sep 29, 2024 |
| Vanguard Group Inc | 3.57% | 1,949,551 | 1.63M | Sep 29, 2024 |
| Neuberger Berman Group, LLC | 3.26% | 1,781,360 | 1.49M | Sep 29, 2024 |
| Sargent Investment Group, LLC | 2.97% | 1,626,247 | 1.36M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.38% | 1,302,216 | 1.09M | Sep 29, 2024 |
| Neuberger & Berman Intrinsic Value Fd | 1.33% | 726,136 | 608.79K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.04% | 568,233 | 476.41K | Sep 29, 2024 |
| JNL Series Trust-JNL/Multi Manager Small Cap GrowthFd | 0.99% | 541,568 | 454.05K | Sep 29, 2024 |
| USAA Mutual Fund Tr-Small Cap Stock Fund | 0.65% | 357,974 | 300.13K | Jul 30, 2024 |
| Fidelity Extended Market Index Fund | 0.47% | 259,695 | 217.73K | Oct 30, 2024 |